CLBS 16
Alternative Names: Autologous stem cell therapy for coronary microvascular dysfunction - Lisata Therapeutics; CD34+ cell therapy - Lisata Therapeutics; CLBS-16; CLBS14-CMD; LSTA-16; XOWNALatest Information Update: 06 Jan 2023
At a glance
- Originator Caladrius Biosciences
- Developer Lisata Therapeutics
- Class Cardiovascular therapies; Haematopoietic stem cells therapies; Stem cell therapies
- Mechanism of Action Angiogenesis inducing agents; Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Cardiomyopathies
Most Recent Events
- 02 Dec 2022 CLBS 16 is available for licensing as of 02 Dec 2022. https://www.lisata.com/clinical-stage-pharmaceutical-company/ (Lisata Therapeutics pipeline, December 2022)
- 17 Oct 2022 Caladrius Biosciences terminates the phase IIb FREEDOM trial in Cardiomyopathies in USA (Intracoronary), as per sponsors decision (NCT04614467)
- 14 Sep 2022 Cend Therapeutics has merged with Caladrius Biosciences to form Lisata Therapeutics